FDA or­ders Karyopharm to halt en­roll­ment for all se­linex­or tri­als, cit­ing in­com­plete safe­ty warn­ing

Late Fri­day night Karyopharm Ther­a­peu­tics $KPT alert­ed in­vestors that the FDA has slapped a par­tial hold on all stud­ies in­volv­ing its lead can­cer drug se­linex­or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER